RxDoctor Payments DataLook up a doctor →

John Anthony, MD

Dermatology · Montgomery, ALNPI 1184790479

Payments from drug & device makers

$18,888in general payments, 2019–2025

Across 915 payments — averaging $20.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Johnson & Johnson$2K
  • Novartis$2K
  • UCB, Inc.$1K
  • Regeneron Healthcare Solutions, Inc.$1K
  • Sanofi$1K
  • plus $7K from 31 others

What the payments were for

  • Food & beverage$18,66199%
  • Education$2271%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,888 in reported general payments places this provider in the 80th percentile of 168 dermatology providers in Alabama.

See all dermatology providers in Alabama

Medicare billing

Part B allowed, 2024
$231,469
Medicare patients
559
Services billed
3,758

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RinvoqUpadacitinib13$79,224
OtezlaApremilast16$76,550
Cosentyx Sensoready (2 Pens)Secukinumab11$75,827
Acitretin11$6,739
Clobetasol Propionate67$3,617
Fluorouracil35$2,828
Metronidazole42$2,516
Tacrolimus12$2,139
Doxycycline Hyclate75$1,891
Ketoconazole79$1,661
Imiquimod42$1,464
Minocycline Hcl44$1,342
Halobetasol Propionate20$1,238
Clindamycin Phosphate27$1,078
Fluocinonide20$828

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$4,150$79,22413 claims
AmgenOtezla$861$76,55016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 168 dermatology providers in Alabama.

Other dermatology in Montgomery

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →